Mozobil

Drug - Mozobil (Plerixafor) [Genzyme]

March 2012

Therapeutic area - Stem Cell Transplant

Approval criteria

• Patient has diagnosis of non-Hodgkin's lymphoma (diagnosis code range 202.80-202.98) or multiple myeloma AND
• Patient is, or will be, concurrently taking G-CSF (i.e. Neupogen) to mobilize hematopoietic stem cells 

Dosing

Estimated CrCl (mL/min) is > 50 dose is 0.24 mg/day (not to exceed 24 mg/day). If CrCl ≤50 reduce dose to 0.16 mg/kg (not to exceed 24 mg/day).

Background information

Plerixafor (Mozobil) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Due to the cost prohibitive nature of Mozobil, the medication is intended to be used in assisting in the mobilization of stem cells for patients who previously or are currently failing to meet their target collection goal.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411